Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Observational Study Assessing the Safety, Efficacy and Treatment Adherence of Nevirapine Extended Release (Combined With Other Antiretroviral Drugs) in HIV Infected Patients in Daily Clinical Practice
Studieoversigt
Status
Status
Betingelser
Betingelser
Detaljeret beskrivelse
Study Design:
non-interventional uncontrolled observational study
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
-
Bialystok, Polen
- Boehringer Ingelheim Investigational Site 8
-
Bialystok, Polen
- Boehringer Ingelheim Investigational Site 7
-
Bydgoszcz, Polen
- Boehringer Ingelheim Investigational Site 9
-
Bydgoszcz, Polen
- Boehringer Ingelheim Investigational Site 10
-
Chorzów, Polen
- Boehringer Ingelheim Investigational Site 11
-
Chorzów, Polen
- Boehringer Ingelheim Investigational Site 12
-
Gdañsk, Polen
- Boehringer Ingelheim Investigational Site 13
-
Gdañsk, Polen
- Boehringer Ingelheim Investigational Site 14
-
Gdañsk, Polen
- Boehringer Ingelheim Investigational Site 15
-
Kraków, Polen
- Boehringer Ingelheim Investigational Site 16
-
Kraków, Polen
- Boehringer Ingelheim Investigational Site 17
-
Poznañ, Polen
- Boehringer Ingelheim Investigational Site 18
-
Wroc£aw, Polen
- Boehringer Ingelheim Investigational Site 19
-
Wroc£aw, Polen
- Boehringer Ingelheim Investigational Site 20
-
-
-
-
-
Bacau, Rumænien
- Boehringer Ingelheim Investigational Site 50
-
Brasov, Rumænien
- Boehringer Ingelheim Investigational Site 51
-
Brasov, Rumænien
- Boehringer Ingelheim Investigational Site 52
-
Brasov, Rumænien
- Boehringer Ingelheim Investigational Site 53
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 21
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 22
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 23
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 24
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 25
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 26
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 27
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 28
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 29
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 30
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 31
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 32
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 33
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 34
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 35
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 36
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 37
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 38
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 39
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 40
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 41
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 42
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 43
-
Bucuresti, Rumænien
- Boehringer Ingelheim Investigational Site 44
-
Constanta, Rumænien
- Boehringer Ingelheim Investigational Site 46
-
Constanta, Rumænien
- Boehringer Ingelheim Investigational Site 47
-
Constanta, Rumænien
- Boehringer Ingelheim Investigational Site 48
-
Giurgiu, Rumænien
- Boehringer Ingelheim Investigational Site 45
-
Ploiesti, Rumænien
- Boehringer Ingelheim Investigational Site 49
-
-
-
-
-
Graz, Østrig
- Boehringer Ingelheim Investigational Site 6
-
Salzburg, Østrig
- Boehringer Ingelheim Investigational Site 5
-
Vienna, Østrig
- Boehringer Ingelheim Investigational Site 1
-
Vienna, Østrig
- Boehringer Ingelheim Investigational Site 2
-
Vienna, Østrig
- Boehringer Ingelheim Investigational Site 3
-
Wels, Østrig
- Boehringer Ingelheim Investigational Site 4
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion criteria:
- HIV-1 infected male and female 18 years and above;
- anti-retroviral therapy (ART) naive and pre-treated patients switching from a nevirapine immediate release or other ART.
Exclusion criteria:
Consistent with the current VIRAMUNE prolonged release SPC.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
|---|
|
nevirapine extended release
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Patients Reporting Non-serious Adverse Events, Serious Adverse Events, and Non-serious and Serious Adverse Events Leading to Treatment Discontinuation
Tidsramme: up to 72 weeks
|
The primary endpoint is to evaluate the safety of a highly active antiretroviral therapy (HAART) that includes nevirapine extended release in routine clinical practice which is to assess the number of patients reporting non-serious adverse events (nSAEs), the number of patients with serious adverse events (SAE), the number of patients with non-serious adverse events leading to treatment discontinuation, and the number of patients with serious adverse events leading to discontinuation.
|
up to 72 weeks
|
|
Number of Patients Reporting Rash of Any Severity
Tidsramme: up to 72 weeks
|
Number of patients reporting rash of any severity as adverse event
|
up to 72 weeks
|
|
Number of Patients Reporting Hepatic Events
Tidsramme: up to 72 weeks
|
Number of patients reporting hepatic events either as adverse event (AE) or as laboratory abnormality of Grade 1 to Grade 4 in aspartate aminotransferase (AST), alanine transaminase (ALT), Gamma-Glutamyl-Transferase (Gamma-GT) and bilirubin.
|
up to 72 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Patients With Virologic Response at Week 24 (Viral Load <50 Copies/mL)
Tidsramme: 24 weeks
|
Virologic response is defined as confirmed Human Immunodeficiency Virus (HIV) viral load of < 50 copies/mL (at two consecutive measurements after baseline) up to week 24 and without subsequent rebound or change of anti-retroviral (ARV) therapy up to week 24.
A rebound is defined as two consecutive measurements of viral load (VL) ≥ 50 copies/mL, at least two weeks apart, after two consecutive measurements of VL< 50 copies/mL.
A change of ARV therapy is defined as a permanent discontinuation of nevirapine extended release, addition of new ARV drugs, or alteration in background therapy.
A change in the background therapy due to toxicity or intolerance is not considered as treatment failure.
If no follow-up viral load was available the virologic response is Missing.
|
24 weeks
|
|
Change in CD4+ Cell Count From Baseline to Week 24
Tidsramme: baseline and week 24
|
The change in the Cluster of differentiation 4 (CD4+) cell count from baseline after 24 weeks was calculated by subtracting the baseline value from the value after 24 weeks.
Therefore, a positive change represents an increase in CD4+ cell count.
|
baseline and week 24
|
|
Change in Morisky Medication Adherence Scale Score From Baseline to 24 Weeks
Tidsramme: baseline and week 24
|
The Morisky Medication Adherence scale (MMAS-8 scale) is a recognized indicator of medication adherence, consisting of 8 questions with a sum score ranging between 0 and 8 points.
The higher score indicates higher adherence to the prescribed therapy recommendation.
It has been agreed that the score of 8 could be categorized as having high adherence, score between 6 and 7 as medium adherence and scores of 5 and less as low adherence.
The change is presented as the score after 24 weeks minus the score at baseline.
Therefore, a positive change score reflects an improvement in the adherence.
|
baseline and week 24
|
|
Number of Patients Reporting Once Daily Nevirapine Intake More Convenient Than Twice Daily Formulation
Tidsramme: 24 weeks
|
The number of patients reporting that they find the once daily nevirapine intake more / very much more convenient than the twice daily formulation.
|
24 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 1100.1550
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .